815 related articles for article (PubMed ID: 28921650)
1. Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.
Vezina HE; Cotreau M; Han TH; Gupta M
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S11-S25. PubMed ID: 28921650
[TBL] [Abstract][Full Text] [Related]
2. Antibody-drug conjugates for cancer.
Chau CH; Steeg PS; Figg WD
Lancet; 2019 Aug; 394(10200):793-804. PubMed ID: 31478503
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacology strategies in supporting drug development and approval of antibody-drug conjugates in oncology.
Liu SN; Li C
Cancer Chemother Pharmacol; 2021 Jun; 87(6):743-765. PubMed ID: 33792763
[TBL] [Abstract][Full Text] [Related]
4. Antibody drug conjugates under investigation in phase I and phase II clinical trials for gastrointestinal cancer.
Leal AD; Krishnamurthy A; Head L; Messersmith WA
Expert Opin Investig Drugs; 2018 Nov; 27(11):901-916. PubMed ID: 30359534
[TBL] [Abstract][Full Text] [Related]
5. Antibody-drug conjugates: Current status and future perspectives.
Gébleux R; Casi G
Pharmacol Ther; 2016 Nov; 167():48-59. PubMed ID: 27492898
[TBL] [Abstract][Full Text] [Related]
6. Antibody-targeted drugs and drug resistance--challenges and solutions.
Shefet-Carasso L; Benhar I
Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
[TBL] [Abstract][Full Text] [Related]
7. Practical considerations for the pharmacokinetic and immunogenic assessment of antibody-drug conjugates.
Sauerborn M; van Dongen W
BioDrugs; 2014 Aug; 28(4):383-91. PubMed ID: 24842227
[TBL] [Abstract][Full Text] [Related]
8. Antibody-drug conjugates: Principles and opportunities.
Phuna ZX; Kumar PA; Haroun E; Dutta D; Lim SH
Life Sci; 2024 Jun; 347():122676. PubMed ID: 38688384
[TBL] [Abstract][Full Text] [Related]
9. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
Yamada K; Ito Y
Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates.
Kamath AV; Iyer S
Pharm Res; 2015 Nov; 32(11):3470-9. PubMed ID: 25446773
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.
Malik P; Phipps C; Edginton A; Blay J
Pharm Res; 2017 Dec; 34(12):2579-2595. PubMed ID: 28924691
[TBL] [Abstract][Full Text] [Related]
12. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.
Donaghy H
MAbs; 2016; 8(4):659-71. PubMed ID: 27045800
[TBL] [Abstract][Full Text] [Related]
13. [Design of next generation antibody drug conjugates].
Zhu GD; Fu YX
Yao Xue Xue Bao; 2013 Jul; 48(7):1053-70. PubMed ID: 24133971
[TBL] [Abstract][Full Text] [Related]
14. Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy.
Nasiri H; Valedkarimi Z; Aghebati-Maleki L; Majidi J
J Cell Physiol; 2018 Sep; 233(9):6441-6457. PubMed ID: 29319167
[TBL] [Abstract][Full Text] [Related]
15. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
[TBL] [Abstract][Full Text] [Related]
16. Strategies and challenges for the next generation of antibody-drug conjugates.
Beck A; Goetsch L; Dumontet C; Corvaïa N
Nat Rev Drug Discov; 2017 May; 16(5):315-337. PubMed ID: 28303026
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Small Antibody Fragments as Strategy to Deliver Therapeutic Payloads.
Aguiar S; Dias J; Manuel AM; Russo R; Gois PMP; da Silva FA; Goncalves J
Adv Protein Chem Struct Biol; 2018; 112():143-182. PubMed ID: 29680236
[TBL] [Abstract][Full Text] [Related]
18. Antibody-Drug Conjugates for Cancer Therapy.
Hafeez U; Parakh S; Gan HK; Scott AM
Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383
[TBL] [Abstract][Full Text] [Related]
19. A Brief Introduction to Antibody-Drug Conjugates for Toxicologic Pathologists.
Mecklenburg L
Toxicol Pathol; 2018 Oct; 46(7):746-752. PubMed ID: 30295169
[TBL] [Abstract][Full Text] [Related]
20. Antibody-Drug Conjugates Containing Payloads from Marine Origin.
Cheng-Sánchez I; Moya-Utrera F; Porras-Alcalá C; López-Romero JM; Sarabia F
Mar Drugs; 2022 Jul; 20(8):. PubMed ID: 36005497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]